We are pleased to announce the availability of the above-mentioned report, which came out in July 2013. Published regularly since 1984, this new report has been updated with data collected in some seventy countries over the last three years. It provides sales data in units, dollars, and market shares by company and by region for each of the therapeutic plasma and recombinant proteins listed below. Pricing trends over the last ten years, and projections to 2012 are also provided.

• Polyvalent Intravenous Immune Globulin (IVIG)
• Polyvalent Intramuscular/Subcutaneous Immune Globulin
• Hyperimmune Globulins (Tetanus, Rho(D), Hepatitis B, Rabies, etc.

• Albumin
• Factor VIII and Factor IX (plasma-derived and recombinant)
• von Willebrand Factor,
• Prothrombin Complex
• Activated Prothrombin Complex and recombinant Factor VIIa

• Additional Factor Proteins (Factor X, XIII, etc.

• Antithrombin III
• Alpha-1 Antitrypsin
• Fibrin Adhesive, and
• Thrombin

This study analyzes recent industry developments that have led the global plasma protein market to grow from about $11.3 billion to $13.3 billion between 2008 and 2010 and even higher in 2012. Its table of contents is enclosed.





JULY 2013


Introduction 3
Executive Summary
Worldwide market by Region 18
Worldwide market by Product 22
Worldwide market by Company
Company Profiles 29
Polyvalent Intramuscular/Subcutaneous Immune Globulin (IMIG) 40
Polyvalent Intravenous Immune Globulin (IVIG) 46
Tetanus Immune Globulin 54
Rho(D) Immune Globulin 60
Hepatitis B Immune Globulin (IM/IV) 66
Rabies Hyperimmune Globulin 73
Cytomegalovirus Hyperimmune Globulin (CMV) 79
Allergy Hyperimmune Globulin 81
All Other Hyperimmune Globulin 84
Albumin and Plasma Protein Fraction (PPF) 85
Factor VIII 92
Factor IX 106
Prothrombin Complex (PCC/PPSB) 115
Activated Prothrombin Complex & Recombinant Factor VIIa 117
von Willebrand Factor 119
Antithrombin III 122
Alpha-1 Antitrypsin 128
Fibrin Adhesives 134
All Other Products 140